Background. The antibody responses against human papillomavirus type 16 (HPV-16) and HPV-18 are well known, but many genital HPV types are oncogenic. We assessed the correlation between detection of type-specific HPV DNA and antibodies for 11 HPV types.
Human papillomavirus (HPV) infection is a causal agent for cervical cancer, other anogenital and some oropharyngeal cancers [1] . Based on a meta-analysis of HPV DNA prevalence among patients with invasive cervical cancer [2, 3] as compared to those with normal cervical cytologic findings [4] , 12 HPV types (HPV-16, -18, -31, -33, -35, -39, -45, -51, -52, -56, -58, and -59) are established as carcinogens in humans, while HPV-68 is probably carcinogenic [2] .
Epidemiological studies based on HPV DNA detection in the cervix underestimate the cumulative exposure of the population to HPV. Meta-analysis of HPV DNA persistence [5] and a recent comprehensive report of HPV DNA incidence and persistence in young women [6] showed that HPV infections are mainly transient. This was described to be an obstacle when assessing virus exposure in the population for designing an HPV vaccination programs: many currently HPV DNA-negative women were previously exposed to HPV [7] . A stabler and more accessible marker is required to design vaccination strategies [7] and to monitor changes of HPV prevalence in a population after HPV vaccination.
Anti-HPV antibodies were suggested to reflect lifetime HPV exposure, but not all HPV infections lead to measurable seroconversion [8] . Consequently, HPV serological assays are not used in clinical settings [9] . Persistent HPV infections lead to seroconversion more often than transient infections [10] , and anti-HPV-16 and anti-HPV-18 antibodies indicate a higher risk for development of clinical disease [11] .
A vaccine against 9 HPV types has prompted seroepidemiological studies of multiple HPV types [12] [13] [14] . Seroepidemiological characteristics of HPV infection were extensively described for the most common carcinogenic HPV types, such as HPV-16 and HPV-18 [15] [16] [17] , but less is known about other high-risk HPV types. As indicated by DNA detection studies, antibodies to HPV-16 appear several months after infection [18] , and levels are generally stable over time [19, 20] , but for other HPV types data on the association between HPV type-specific seropositivity and HPV DNA positivity are limited and inconsistent [21] [22] [23] [24] [25] . For example, a recent report using multiplexed detection of antibodies to HPV demonstrated statistically significant concordance between detection of antibodies and detection of HPV DNA for HPV-33, -52, and 58 but not for HPV-16, -18, -31, and -45 [22] .
Studies to detect type-specific HPV DNA and antibodies provide the most complete information on HPV exposure. We investigated positivity for serum anti-HPV antibodies and HPV DNA in a large, population-based cohort of Slovenian women attending the national cervical cancer screening program 2 times (3 years apart) [26, 27] . For this cohort, we previously reported antibody responses to 21 different HPV types in serum samples collected at enrollment and found that approximately half of HPV DNA-positive subjects were concomitantly positive for serum antibodies of the same HPV type [24] . However, as antibodies are supposed to reflect cumulative exposure, we reasoned that validation of serological findings should not use just measurements at a single point in time, but should use serial measurements of HPV DNA positivity in longitudinally collected samples. Therefore, we characterized the dynamics of the antibody responses to multiple anogenital HPV types and their correlation with the cumulative presence of HPV DNA of the same type in longitudinally collected serial samples.
METHODS

Study Population
The study population and the protocol were as described previously [26, 27] . Briefly, cervical smear specimens and serum samples were collected from 2037 women, who participated in the organized national cervical cancer screening program in Slovenia and were 20-64 years old at enrollment. Women who were vaccinated against HPV (n = 13) were excluded from the study. Data on HPV DNA presence and serological test results for the remaining 2024 participants were used in the current study. Of these, 1839 women reported information about their lifetime number of sex partners and about new sex partner(s) at follow-up as compared to the baseline visit.
The presence of HPV DNA and anti-HPV antibodies at baseline, during follow-up, and cumulatively were determined for 1848 women (average age at enrollment, 37.1 years; median age, 36 years). The strength of association between seroconversion and new sexual partner(s) was estimated for the 1839 women who had reported number of partners in a questionnaire. Determinants of seroreversion were not addressed in this study.
Ethical Approval
Each round of the study was conducted in accordance with the ethical standards of the Helsinki Declaration and was approved by the National Medical Ethics Committee at the Ministry of Health of the Republic of Slovenia (consent numbers for the baseline and second screening round of the study: 83/11/09 and 109/08/12, respectively). Written informed consent was obtained from all study participants.
HPV DNA Genotyping
HPV DNA genotyping was performed as described elsewhere [26, 27] . All cervical samples were tested for the presence of 14 HPV types with the RealTime High Risk HPV assay (Abbott), allowing genotyping of HPV-16, and HPV-18 and aggregated detection of HPV-31, -33, -35, -39, -45, -51, -52, -56, -58, -59, -66, and -68. At baseline, cervical smear specimens were also tested with the Hybrid Capture 2 HPV DNA assay (Qiagen) [27] .
RealTime High Risk HPV assay-positive samples were additionally tested for 37 HPV genotypes, using the Linear Array HPV Genotyping Test (Roche Molecular Diagnostics), which also allows genotyping of the low-risk types HPV-6, -11, and -73, although testing for these 3 types was only performed for 27.7% of the follow-up samples (560 of 2024). At both screening rounds, HPV-52-specific real-time polymerase chain reaction (PCR) analysis, the INNO-LiPA HPV Genotyping Extra Test (Innogenetics), and an in-house GP5+/GP6+ PCR analysis were used as confirmatory tests, as previously described [26, 27] .
HPV Serological Testing
The presence of anti-HPV antibodies was determined with a multiplexed assay, using pseudovirions of HPV-6, -11, -16, -18, -31, -33, -35, -39, -45, -52, -56, -58, -59, -68, and -73 [24] . Cutoffs for seropositivity were calculated with a negative control serum panel from 235 children ≤12 years old (average age, 4.8 years). For each type of HPV, cutoffs were assigned as described in the World Health Organization HPV Laboratory Manual (ie, by calculating the average of mean fluorescence intensities [MFIs] of a negative control serum panel +3 SDs) [28] .
Assay concordance between baseline and follow-up testing was assessed by retesting of 133 samples positive for 1 or multiple HPV types that had been tested in the first screening round (ie, "bridging samples"). Agreement between continuous and categorical data (reflected by R 2 and κ coefficients) from each test period was estimated. To increase the assay interrater reliability, alternative thresholds for seropositivity were used: the initial cutoffs for each HPV type were multiplied by a type-specific coefficient (the follow-up to baseline ratios of the average MFIs of bridging samples). Alternative cutoffs for HPV-16, -33, -39, -45, -56, -58, -59, -68, and -73 were increased to a previously established minimum MFI of 250 and further reevaluated for the assay interrater reliability agreement. HPV-31 and -35 alternative cutoffs were further replaced with higher values and reestimated. Average goodness of fit (R 2 ) and categorical data (κ) agreement for alternative cutoffs were 0.8 (Supplementary Table 1) .
Interassay reproducibility was assessed by retesting positive and negative controls in duplicates in each run. For all HPV types, the mean coefficient of variation (CV) was 30.6% (median, 26.7%). Intraassay reproducibility (ie, between different plates in the same run) was assessed by multiple retesting of serum specimens positive for 7 HPV types (mean CV for 7 HPVs, 11.1%; median CV, 11.5%).
Statistical Analysis
Concordances were determined with κ statistics (for categorical data agreement) and R 2 (for numerical data agreement). Estimated 95% confidence intervals (CIs) for HPV DNA and type-specific antibody prevalence were determined using the Wilson/Brown method. Statistical analyses were performed using GraphPad Prism 7.01 for Windows (GraphPad Software, La Jolla, CA; available at: http://www.graphpad.com). The sensitivity of the serological assay was defined as the proportion of HPV DNA-positive women who were seropositive for a given HPV type, and specificity was calculated as the proportion of HPV DNA-negative women who were seronegative. Seroconversion was defined as seropositivity at follow-up among women who had been seronegative at baseline. Odds ratios (ORs) and 95% CIs were calculated with the StatCalc module of Epi Info7.
RESULTS
Serum antibodies were significantly correlated with the presence of HPV DNA for 10 HPV types (ie, HPV-16, -18, -31, -33, -35, -39, -45, -52, -56, and -58; Table 1 ). The median sensitivity was 47.4%, which increased to 51.5% if the presence of HPV DNA in the sample collected 3 years earlier from the same person was included in the analysis. When considering either the current or cumulative presence of HPV DNA, the median specificity of serological analysis was similar (88.2% and 88.3%, respectively; Table 1 ). When considering the cumulative presence of HPV DNA, the sensitivity for different HPV types ranged between 28.6% (for HPV-45) and 73.3% (for HPV-58), and the specificity varied between 77.1% (for HPV-16) and 94.5% (for HPV-45; Table 1 ).
The median OR for the association between type-specific seropositivity and HPV DNA positivity at the same time was 7.5 (95% CI, 2.2-26.1; Table 1 ). Considering also the result of the previous HPV DNA test, the OR was similar, but the CI was much narrower because of the larger number of observations (OR 7.4; 95% CI, 4.2-12.8; Table 1 ). For the only HPV type for which the presence of antibodies did not have a significant association with the presence of HPV DNA at the cervix (ie, HPV-59; OR, 1.8; 95% CI, .5-6.5), a strong association was detected when HPV DNA positivity 3 years earlier was also considered (OR, 6.6; 95% CI, 3.4-13.0; Table 1 ).
Cumulative HPV DNA prevalence and seroprevalence are shown in Table 2 . According to grouped estimates of the seroprevalence of vaccine-targeted types, 67.1% of women were seropositive for at least 1 HPV type included in the nonavalent vaccine, 53.6% were positive for HPV-6/-11/-16/-18, and 37.6% had detectable antibodies against HPV-16/18 when seropositivity 3 years earlier was considered in estimates (Supplementary Table 2 ). Seroprevalence of any of the 5 high-risk non-16/18 HPV vaccine types (ie, HPV-31/-33/-45/-52/-58) was 45.4%.
In cumulative estimates, seropositivity against at least 2 HPV types was detected in 53.3% of women. At any of the testing occasions, seropositive women were likely to have type-specific antibodies against, on average, 3 HPV types (data not shown). Antibodies to the various HPV types were mostly stable during 3 years: if the first sample revealed seropositivity, the likelihood for seropositivity 3 years later was 63.1% (this reflects the median of the likelihoods for all investigated HPV types; Table 3 ). A high likelihood for seropersistence was found for HPV-56 (85.7%), HPV-59 (83.0%), HPV-58 (77.3%), HPV-16 (76.0%), and HPV-31 (75.2%), whereas type-specific antibodies to HPV-35 (seropersistence, 40.3%), HPV-39 (49.5%), and HPV-45 (52.6%) were more likely to drop below detection levels at follow-up. Seroconversion (ie, appearance of antibodies in women previously seronegative for the antibodies) was particularly common for HPV-35 (9.7%), as well as for the low-risk HPV types HPV-6 (10.5%) and HPV-11 (8.0%; Table 3 ).
For most HPV types studied (ie, HPV-16, -31, -39, -45, -52, -56, -58, and -59), we observed strong and statistically significant associations between seroconversion and the presence of cervical HPV DNA at baseline (Table 4) . For HPV-18, -33, and -35, for which we did not detect a statistically significant association, the point estimates for the association between seroconversion and the presence of baseline cervical HPV DNA were also positive (Table 4) . Detection of HPV DNA in a seronegative woman was strongly associated with an increased likelihood of seroconversion at the follow-up visit, especially for HPV-58 (OR, 46.2; 95% CI, 8.3-257.0) and HPV-39 (OR, 24.9; 95% CI, 7.3-84.8).
We also investigated whether self-report of new sex partners affected the likelihood for seroconversion (Supplementary Table 3 ). During the 3-year follow-up, 25.5% of women (469 of Table 3 ).
DISCUSSION
We found that several known characteristics of antibodies to the most common oncogenic HPV types (HPV-16 and HPV-18) apply to the 11 anogenital HPV types assessed in this study:
(1) association with detection of cervical HPV DNA of the same type, (2) stability over time, (3) delayed appearance as compared to HPV DNA, and (4) sensitivity of detection (using cervical HPV DNA analysis as a gold standard) of around 50%. Based on our findings, it seems reasonable to always include data on HPV DNA positivity in a preceding sample in serological validation studies, since this may improve detection sensitivity without impairing specificity and will increase the statistical power of the study. Finally, we report that dual use of both HPV serological analysis and HPV DNA testing in serial samples appears to be useful for measuring cumulative exposure to various HPV types in a cohort of HPV DNA-positive and HPV DNA-negative women. The study has several unique strengths. It was nested within a population-based, organized cervical screening program with one of the highest population coverages in Europe. Therefore, our findings could be extended to the general female population in this part of the world. Additionally, it was large, had prolonged 3-year follow-up with 2 serial visits of the same women, and performed extensive, validated testing for both HPV antibodies and HPV DNA [24, 29] . We present all crude data from DNA genotyping and seroprevalence studies performed at baseline and at follow-up. We also show that data from the cumulative measurements improved the single point estimates. Our study is timely, as studying associations between type-specific HPV DNA and antibodies may now be affected by vaccination against HPV: HPV DNA prevalence declines in populations, whereas vaccine-related antibodies are at present. Distinguishing between vaccine-related and naturally derived HPV antibodies will be a challenge.
Limitations include the fact that we produced pseudovirions and tested for type-specific antibodies only against 15 HPV types and that HPV DNA genotyping targeted only the oncogenic HPV types. Thus, although there are 12 HPV types established to be oncogenic [2] , we had complete data on both antibodies and HPV DNA only for 11 HPV types (HPV-16, -18, -31, -33, -35, -39, -45, -52, -56, -58, and -59). The evaluation of type-specific concordance between DNA and antibodies for the probably oncogenic HPV-68 was not performed, since the HPV DNA genotyping assay evaluated only HPV-68 subtype B [27] and the serological assay used pseudovirions from HPV-68 subtype A.
When estimated with single-time-point DNA positivity, pseudovirion-Luminex assay sensitivity was the lowest among the alpha-7 HPV types (ie, HPV-18, -39, -45 and -59). HPV DNA positivity measured at both time points improved sensitivity for HPV-39 and HPV-59 but not for the other phylogenetically closely related types. The reasons for this phenomenon are not known, although it could be caused by a faster time to clearance of the infection, a longer time from infection to seroconversion, or probable variability in the immunogenic properties across the HPV subtypes. This is supported by a previously described decrease in anti-HPV-18 antibody titers as compared to the other vaccine-included types detected with competitive Luminex immunoassay [30] and the reported stability of HPV-18 virus-like particles being inferior to HPV-6/11/16, based on enzyme-linked immunosorbent assay findings [31] . Still, to the best of our knowledge, our serological assay, using pseudovirions Median seroconversion frequencies were 5.8 for the group negative for HPV DNA at baseline and 36.4% for the group positive for HPV DNA at baseline, and the median OR was 10.8.
Abbreviations: CI, confidence interval; OR, odds ratio.
a Acquired type-specific seropositivity among the seronegative at baseline cases.
from 15 different genital HPV types, is the widest pseudovirion-based serology panel as yet described in the literature. Since serum samples were collected and tested 3 years apart, the potential problem with assay drift (defined as a change in assay performance over time) was investigated by retesting the samples from the first screening round concomitantly with testing of samples from the second visit. The κ statistic revealed good or very good agreement between results of initial and repeat testing, and assay drift was excluded as a potential problem.
Similar to the control over the assay drift, virus-like particles in each batch of the in-house test kit were monitored for potential cross-reactivity, using international serum standard for HPV-16 and HPV-18 and in-house serum standards previously testing positive in a monospecific way. Residual cross-reactivity among the closely related types could potentially show up once the panel of HPV types gets further expanded. Also, despite the high correlation of anti-HPV antibodies with presence of HPV DNA of the same type, seropositivity to multiple HPV types to certain extend can be attributable to the cross-reactivity [32] . Scherpenisse et al found that naturally acquired anti-HPV antibodies from sera positive for a single type were highly genotype specific, whereas in sera positive for multiple types cross-reactive antibodies were observed [32] .
Our conclusions are in line with those from other, similar studies. Many reports have established that antibodies to HPV virus particles (ie, both virus-like particles and pseudovirions) are stabler markers for estimation of the cumulative exposure to a HPV in a population [19, 20, 33, 34] , at least in the case of HPV-16. Our finding that HPV DNA prevalences mostly decline over time is also in agreement with findings of previous studies establishing that HPV DNA tends to be transiently detectable and declines in prevalence with increasing age. It is well known that the median duration of HPV DNA detectability is only about 14 months [6] . Therefore, studies based only on results of HPV DNA testing greatly underestimate the total exposure to HPV in a population. HPV seroprevalences, in contrast, were shown to be rather stable. This further supports the hypothesis that type-specific antibody positivity to HPV could serve as a better indicator of cumulative exposure to the virus. The facts that not all HPV DNA infections lead to seroconversion (imperfect sensitivity) and that a detectable antibody response has a delayed appearance are also well known for HPV-16 [8] .
Previous studies have compared HPV DNA detection with concomitant presence of type-specific antibodies to multiple HPV types, using bacterial fusion proteins (GST-L1). Our study is in agreement with a longitudinal study from Chile [34] but differs somewhat from a recent study in the Netherlands that found a significant association between antibodies to HPV GST-L1 proteins and HPV DNA only for 3 of 7 studied HPV types [22] . Compared with serological analysis using GST-L1 bacterial fusion proteins, pseudovirion-based serological testing in a previous study on cutaneous HPV types showed a superior correlation with the presence of HPV DNA [35] .
Our strategy to use a combination of HPV DNA testing and pseudovirion-based serological analysis appears to be the best approach to reliably measure the type-specific prevalence of HPV. The same pseudovirion-based method as in our study was recently used in investigation of a prevaccination seroprevalence to HPV among 259 women in Italy [36] . HPV-16 and HPV-6 were similarly found to be particularly prevalent [36] .
Seroprevalences of antibodies to several HPV types that are present in the nonavalent HPV vaccine but not in the quadrivalent vaccine were relatively high in our study population. For example, antibodies against HPV-31 and HPV-58 were detected in more than one fifth of women. Our results imply that the nonavalent vaccine has the potential to further reduce the proportion of women in the population that may have a positive result of a screening test in HPV-based screening programs.
Our data on the stability of HPV antibodies is similar to the largest study so far about the dynamics of HPV-16 antibodies, which included 7986 Costa Rica women followed up for 5-7 years [37] . A total of 55.5% of women remained HPV-16 seropositive over the follow-up time, which is comparable to our findings (in 76.0% of participants, antibodies to HPV-16 remained detectable after 3 years) [37] .
The seroconversion rate for HPV-16 was 7% in the present study, whereas in the Costa Rica cohort 6% of seronegative women developed detectable antibody response over the follow-up time [37] .
In conclusion, biological characteristics and associations with HPV DNA for type-specific antibodies to HPV-16, -18, -31, -33, -35, -39, -45, -52, -56, -58, and -59, measured with pseudovirion-based serological tests, are similar to what was previously reported for HPV-16. Pseudovirion-based serological testing for multiple oncogenic HPV types is likely to be useful in further research on HPV vaccines and on the humoral immune responses against HPV infection.
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